News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
HIMSS27 in Copenhagen seeks healthcare IT presentation ideas
HIMSS27 takes place May 19–21, 2026 in Copenhagen. Healthcare IT News is inviting presentation submissions. Details on the checklist for qualified speakers.
Apollo Hospitals Adds AI Layer to 400-Bed Smart Hospital in Hyderabad
Apollo Hospitals' new Hyderabad facility integrates AI-assisted clinical tools into its existing digital backbone, signaling a shift from record-keeping systems to active clinical decision support across India's largest hospital chain.
Regeneron's melanoma combo fails to beat Merck's Keytruda in late-stage trial
Regeneron's fianlimab plus Libtayo did not outperform Keytruda in a late-stage melanoma study, erasing billions in market value and raising questions about the immunotherapy strategy.
FDA reshuffles drug review leadership as Amgen death toll climbs to 20
FDA leadership changes hit two top drug review offices as deaths linked to an Amgen medication reach 20. What triggered the shakeup and what it means for pending approvals.
Merck's China-licensed cancer drug clears first major global trial
Merck advanced a therapy licensed from a Chinese biotech in its first of 17 late-stage trials. The drug is central to the company's plan to hit $70 billion in annual sales by the next decade.
FDA Approves AstraZeneca's Hypertension Drug Targeting Blood-Pressure Enzyme
AstraZeneca's Baxfendy wins FDA clearance as a new class of blood-pressure treatment. The company projects $5B+ annual sales, but the real question is whether doctors will switch patients from cheaper generics.
FDA Covid vaccine deaths report released by lawmaker months late
An FDA-commissioned analysis of pediatric deaths linked to Covid vaccines was published by a Republican congressman after the agency missed its own deadline. What the report found and why the delay matters.
Amgen defends Tavneos as FDA pushes removal and Europe probes data
Amgen is standing firm on its rare disease drug Tavneos despite FDA plans to remove it from the market, European data-integrity concerns, and a Japanese distributor halting new prescriptions. Here's what regulators are seeing.
BioMarin's ENPP1 therapy fails Phase 3 primary endpoint
BioMarin's enzyme replacement therapy for ENPP1 deficiency did not meet its primary clinical endpoint in late-stage testing. The mixed results signal risk for rare disease programs relying on single mechanism trials.
Relay's PI3Kα drug clears rare disease trial, expands beyond breast cancer
Zovegalisib beat Wall Street expectations in Phase 2 vascular anomalies study. The result opens a second indication for Relay's PI3K inhibitor platform.
Nourish hits $1.75B valuation on $100M nutrition telehealth round
Nourish, a virtual nutrition care platform, raised $100M and reached a $1.75B valuation. The funding signals investor confidence in telehealth expansion beyond primary care.
Innowise targets $43B custom software niche in $800B IT outsourcing market
Innowise, a global IT services firm, focuses on mid-market and enterprise clients building custom software, AI engineering, cloud, and legacy modernization. The company competes in a $43B custom development segment within the broader $800B outsourcing market.